biostudies-literatureUnknown40(2)Heerspink HJLBayer AGBayer<h4>Background</h4>Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes in two phase 3 outcome trials. The Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) study investigates the effect of finerenone in adults with CKD without diabetes.<h4>Methods</h4>FIND-CKD (NCT05047263 and EU CT 2023-506897-11-00) is a randomized, double-blind, placebo-controlled phase 3 trial in patients with CKD of non-diabetic aetiology. Adults with a urinary albumin:creatinine ratio (UACR) ≥200-≤3500 mg/g and an estimated glomerular filtration rate (eGFR) ≥25-<90 ml/min/1.73 m2 receiving a maximum Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association308-319https://www.ebi.ac.uk/biostudies/studies/S-EPMC11852274biostudies-literatureDesign and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.PMC11852274Burgner AChang CTKhwaja AKenig YWanner CKidokoro KWong ACGouva CDubois BKang YSBadve SArunkumar SPackham DPetras DVesterinen PHe YBoletis ICherney DZISchloemer PHe WLeiba AFiaccadori ELin HXu XAlla SHeerspink HJLBrinker MDClaes KRehorova JLee CTMortensen LKanno YKendrick JOh JESegura de la Morena JJAhmad MKNakhoul GMeng XTan NCAlves ARTurner JKitagawa KMinutolo RUchimura KCosta JSCheng HTDizayee SBassat OKRozen-Zvi BTeo JLee SHMoussa JMiyamoto KGray NBech JIlieva APBarrios CAntropenko NLee SYAguerre POshikawa JKotzker WAgarwal RGidaro BSzeto CCGelersztein EGupta AChetrit SBPereira THernandez GZilahi ZChiu YLCluigt NBirne RDong JLee JPSantorelli GGriffin SZaidman CJChen XLabriola LXia YChen QIlchev SLi JMaeda YNakamura MChen JChen MChen LAhmad NHMeyer JManllo STChen CLi WMazlan SADHominal MLi YAlmeida ARamanathan SAbe MKopyt NFarber EJaras JHIborra PLLoh CLWirth JNeuen BLDu JBamichas GXiong FAmemiya MSuzuki SBouarich HJamal ALiu LJiang GPrazny MLui SLTamura KRalph RSuzuki HPark JTEzhov AHaviv YLam CSPKirschner RKolkhof PPickett THalac FMendez RHansen DNakaya IUmpierrez GStylianou KUeda SPandey RAlicic RVo NOno MYamauchi ALuo QNemeth ALuo PMisaki TMakita YGovindan SChoi BSFrome APapadopoulou DLiu ALiu BJuhl CLiu FKamijo YCastro CBeberashvili IMatsui MAdnan WAHWMWu MJFIND-CKD investigatorsBucek PYazawa MKhullar DStamova SChen HHSahay MCimino RShi YGrandaliano GPapachristou EPedagogos EHornum MBeckerman PDonati GLa Manna GToda TNewman GLee LYBayram EMaldonado RHornova LNishi HBittar JKanai HMcCafferty KSantana SIKruzel-Davila EEHawley CPerkovic VMasutani KLee JFoote CLevin-Iaina NLee DLee KWQuadrini MDoubel PChang AAbissova TTang SPergola PTeixeira E Costa FCheng HSpeeckaert MTang SCWIshii MKirk ERastogi AYeo SCMirkhel ADoulton TKim SLee KQTeruel JGSuhail SMFujita YAwad AFujii HBansal SLu WZhdanova EWang CLindhardt MWang DChristiano CWang FFujisaki KIvanova YNtounousi EJang HRFujii NSchmidt DGarrit JCWang JIgnatius AFujii TElahi SToyama THan SYChahin MVutova TIwamoto TAko SToyoda MArriola MYakob SRodionova TPark HYang MDimitrova IAnand SYang AKader MASARahman MMajernikova MGracious NAtta MYang XChiu PFHan BGRomero MSPanse SHung CCLin SLLong GLong HChernin GSarafidis PAShimizu HShin SJMavani SGregorini MCKim YHNiu JKoizumi MEsposito COkada HBakris GLWahab MZAKovacs LVasileva AYan RTuttle KRKim YCMaes BThethi TSmith PSmith MPardo SAFung SKSSzelestei TChiang WYTolins JSarafidis PDeben FMfalseDesign and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.<h4>Background</h4>Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes in two phase 3 outcome trials. The Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) study investigates the effect of finerenone in adults with CKD without diabetes.<h4>Methods</h4>FIND-CKD (NCT05047263 and EU CT 2023-506897-11-00) is a randomized, double-blind, placebo-controlled phase 3 trial in patients with CKD of non-diabetic aetiology. Adults with a urinary albumin:creatinine ratio (UACR) ≥200-≤3500 mg/g and an estimated glomerular filtration rate (eGFR) ≥25-<90 ml/min/1.73 m2 receiving a maximum 2025-01-01T00:00:00Z2025 Feb2026-06-01T22:05:41.642Z2025-04-04T13:46:41.499ZS-EPMC118522743885881810.1093/ndt/gfae132